“The Achilles’ heel of CRISPR application is the delivery of sgRNA/Cas9 to the desired tissues.”
Credit: 2023 Thomsen.
“The Achilles’ heel of CRISPR application is the delivery of sgRNA/Cas9 to the desired tissues.”
BUFFALO, NY- November 28, 2023 – A new editorial paper was published in Oncotarget’s Volume 14 on November 27, 2023, entitled, “The double-edge sword of CRISPR application for in vivo studies.”
In this new paper, researcher Martin K. Thomsen from Aarhus University begins his editorial by discussing a hallmark paper that was published a decade ago by Platt et al. on the in vivo application of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to generate cancer in different organs of mice.
This hallmark paper outlines the advancement of delivering sgRNA’s to the target tissue to create loss or gain of function mutations without the need for timely intercrossing of genetic mouse strains. Furthermore, the study showed that multiplexing was possible, thereby enabling the method to target multiple sites simultaneously [1]. It was foreseen that this technology would change the way mouse models of cancer were generated, but even after 10 years, only few studies have relied on this methodology [2].
“The double-edged sword of in vivo application of CRISPR is the imperfection of mutations generated in the target sequence.”
As CRISPR introduces mutations, they do not always occur, resulting in cells being present without the desired mutation. This is further complicated by the different types of indels, which can result in a functional protein with only changes in a few amino acids, without the introduction of a premature stop codon. This introduces clone-to-clone variation and results in tumors with a different mutation profile [3, 4]. However, this is also an advantage of CRISPR for generating in vivo cancer models as natural selection will occur, resulting in a cancer Darwinian evolution.
“Altogether, the in vivo application of CRISPR will become more common, even though the technique has challenges, it will only become more feasible in the future, allowing more researchers to apply this technology.”
Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28459
Correspondence to: Martin K. Thomsen
Email: [email protected]
Keywords: CRISPR, in vivo, mouse models, cancer, Adeno-associated virus
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
- X, formerly known as Twitter
- YouTube
- LabTube
- Soundcloud
Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28459
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact: [email protected].
Oncotarget Journal Office
6666 East Quaker Str., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
Journal
Oncotarget
DOI
10.18632/oncotarget.28459
Method of Research
Commentary/editorial
Subject of Research
People
Article Title
The double-edge sword of CRISPR application for in vivo studies
Article Publication Date
27-Nov-2023
